reports
Editas Medicine Announces EDIT-401 Poster Presentation at the American...
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at the upcoming American Heart Association (AHA) Scientific Sessions 2025 to be held November 7-10 in New Orleans, Louisiana. American Heart Association (AHA) Scientific Sessions 2025Title: A transformative LDL cholesterol–l...
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at ...
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental, potential best-in-class, one-time therapy to significantly reduce LDL-cholesterol (LDL-C), at the 32nd An...
Editas Medicine Announces EDIT-401 Oral Presentation at the European S...
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain. European Society of Gene and Cell Therapy (ESGCT) Congr...
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead...
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on EDIT-401 today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced the nomination of its lead in vivo development candidate, EDIT-401,...
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Ca...
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate. Webinar Presentation Details:The live and archived webcast of the Company’s webinar presentation will be accessible through this , or through the page of the “Inv...
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare ConferenceFormat: One-on-one MeetingsDate: Wednesday, September 3Location: Boston, MA Cantor Global Healthcare ConferenceFormat: Fireside Chat with Webcast and One-on-one MeetingsDate: Thursday, Septembe...
Editas Medicine Announces Second Quarter 2025 Results and Business Upd...
Editas Medicine Announces Second Quarter 2025 Results and Business Updates Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas Presented data at ASGCT, TIDES, and EHA that validate differentiated potential of Editas’ gene upregulation strategy and in vivo delivery platform technology Strong cash position with operational runway into the se...
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delive...
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIR...
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistr...
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene ...
Editas Medicine Reports New In Vivo Data Highlighting the Potential of...
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 p...
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisc...
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared in vivo proof of concept data supporting the development of a potentially first-in-class treatment for an undisclosed liver target in a poster presentation...
Editas Medicine Announces First Quarter 2025 Results and Business Upda...
Editas Medicine Announces First Quarter 2025 Results and Business Updates Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo preclinical proof of concept to upregulate expression of a target liver protein to meaningfully reduce a common disease-associated biomarker at ASGCT this week and TIDES next week Remains on track to declare two in vivo gene editing development candidates via gene upregu...
Editas Medicine Announces U.S. Court of Appeals for the Federal Circui...
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and vacated-in-part the Patent Trial and Appeal Board’s (PTABs) previous decision and remanded it back to the PTAB for further review in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the...
Editas Medicine to Announce First Quarter 2025 Financial Results and t...
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine mana...
Editas Medicine to Present Preclinical Data Demonstrating Progress in ...
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 – 17, 2025, in New Orleans, LA, and virtually. The Company is presenting pr...
Editas Medicine Announces Chief Financial Officer Transition
Editas Medicine Announces Chief Financial Officer Transition Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy Parison will succeed Mr. Lucera as Chief Financial Officer. “We are thrilled to promote Amy to the ex...
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results an...
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneeri...
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Re...
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine m...
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Da...
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Achieved in vivo editing of liver cells in non-human primates and in vivo delivery to two additional cell types in humanized mice Anticipated 2025 milestones include: declare two in vivo development candidates, one in HSCs and one in liver; ...
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare C...
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA. A of the presentation will be available on the “Investors” section of the Editas Medicine website at . An archived replay will be available on the website fo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.